| Description | PG-116800 (PG-530742) is a matrix metalloproteinase (MMP) inhibitor. PG-116800 can be used in studies about the treatment of osteoarthritis. |
| Synonyms | PG-530742, PGE-7113313, PGE 7113313, PG 530742 |
| molecular weight | 501.55 |
| Molecular formula | C24H27N3O7S |
| CAS | 291533-11-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (99.69 mM) |
| References | 1. Hudson MP, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006;48(1):15-20. 2. Krzeski P, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9(5):R109. 3. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res. 2006;69(3):677-687. 4. Rodriguez-Merchan EC. The Current Role of Disease-modifying Osteoarthritis Drugs. Arch Bone Jt Surg. 2023;11(1):11-22. |